Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?

Abstract

Monoclonal antibodies (mAbs) are increasingly being considered as agents to fight severe viral diseases. So far, they have essentially been selected and used on the basis of their virus-neutralizing activity and/or cell-killing activity to blunt viral propagation via direct mechanisms. There is, however, accumulating evidence that they can also induce long-lasting protective antiviral immunity by recruiting the endogenous immune system of infected individuals during the period of immunotherapy. Exploiting this property may revolutionize antiviral mAb-based immunotherapies, with benefits for both patients and healthcare systems.

• Authors: Mireia Pelegrin, Mar Naranjo-Gomez, Marc Piechaczyk
• Journal: Trends in microbiology (Trends Microbiol) Vol. 23 Issue 10 Pg. 653-665 (Oct 2015) ISSN: 1878-4380 [Electronic] England
• PMID: 26433697 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2015 Elsevier Ltd. All rights reserved.

Chemical References

• Antibodies, Monoclonal
• Antibodies, Viral
• Antiviral Agents

Topics

• Antibodies, Monoclonal (immunology, therapeutic use)
• Antibodies, Viral (immunology, therapeutic use)
• Antiviral Agents (immunology, therapeutic use)
• Humans